Robert E. Landry, EVP Finance CFO at REGENERON PHARMACEUTICALS, INC. (REGN), sold 15,958 shares at $682.37 ($10.9M) on 2022-03-29, disclosed to the SEC on 2022-03-30.
Open-market sale of $10.9M REGN by EVP Finance CFO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $685.26 | 1,134 | $777K | 7.1% |
| 2 | $685.26 | 2,785 | $1.9M | 17.4% |
| 3 | $685.26 | 3,183 | $2.2M | 19.9% |
| 4 | $685.26 | 3,581 | $2.5M | 22.4% |
| 5 | $681.90 | 54 | $37K | 0.3% |
| 6 | $682.37 | 103 |
| $70K |
| 0.6% |
| 7 | $682.37 | 103 | $70K | 0.6% |
| 8 | $683.29 | 304 | $208K | 1.9% |
| 9 | $683.29 | 304 | $208K | 1.9% |
| 10 | $684.45 | 227 | $155K | 1.4% |
| 11 | $684.45 | 227 | $155K | 1.4% |
| 12 | $685.58 | 176 | $121K | 1.1% |
| 13 | $685.58 | 176 | $121K | 1.1% |
| 14 | $686.67 | 192 | $132K | 1.2% |
| 15 | $686.67 | 192 | $132K | 1.2% |
| 16 | $687.52 | 220 | $151K | 1.4% |
| 17 | $687.52 | 220 | $151K | 1.4% |
| 18 | $688.55 | 542 | $373K | 3.4% |
| 19 | $688.55 | 542 | $373K | 3.4% |
| 20 | $689.33 | 205 | $141K | 1.3% |
| 21 | $689.33 | 205 | $141K | 1.3% |
| 22 | $690.91 | 37 | $26K | 0.2% |
| 23 | $691.47 | 226 | $156K | 1.4% |
| 24 | $691.47 | 226 | $156K | 1.4% |
| 25 | $692.38 | 147 | $102K | 0.9% |
| 26 | $692.38 | 147 | $102K | 0.9% |
| 27 | $693.18 | 103 | $71K | 0.7% |
| 28 | $693.18 | 103 | $71K | 0.7% |
| 29 | $694.94 | 147 | $102K | 0.9% |
| 30 | $694.94 | 147 | $102K | 0.9% |
| Total | $686.15 avg | 15,958 | $10.9M | 100% |
| Filing → |
| REGN | SELL | 2023-08-25 | $188K | — | Filing → |
| REGN | SELL | 2023-03-29 | $1.8M | — | Filing → |
| REGN | SELL | 2023-02-07 | $2.1M | — | Filing → |